Gritstone bio to Participate in Upcoming Investor Conferences

On September 5, 2023 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported that management will be participating in the following investor conferences (Press release, Gritstone Bio, SEP 5, 2023, View Source [SID1234634891]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2023 Wells Fargo Healthcare Conference (1x1s only)
Conference Dates: September 6 – 8, 2023
Location: Boston, MA

H.C. Wainwright 25th Annual Global Investment Conference (Fireside Chat)
Presentation Date and Time: Wednesday, September 13, 2023 at 11:30am ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: New York, NY
Webcast: View Source

Cantor Global Healthcare Conference (Fireside Chat)
Presentation Date and Time: Thursday, September 28, 2023 at 2:25pm ET
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: New York, NY
Webcast: View Source

JonesTrading 2023 Healthcare Summit (1x1s only)
Conference Dates: October 9 – 11, 2023
Location: Miami, FL

BIO Investor Forum (Panel Participation)
Panel Title: Extending RNA Technology Pipelines into New Tissues and Applications​
Panel Date and Time: Tuesday, October 17, 2023 from 3:00 to 3:50pm PT
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: San Francisco, CA

The live webcasts will also be available via View Source Archived replays will be accessible for 30 days following the event.

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

On September 5, 2023 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET (Press release, GlycoMimetics, SEP 5, 2023, View Source [SID1234634890]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the GlycoMimetics website at View Source An archived recording will be available for 30 days following the event.

Geron to Participate in the Baird 2023 Global Healthcare Conference

On September 5, 2023 Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, reported that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Baird 2023 Global Healthcare Conference in New York City, NY, on Tuesday, September 12, 2023, at 4:55 p.m. ET (Press release, Geron, SEP 5, 2023, View Source [SID1234634889]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available through the Investors and Media section of Geron’s website under Events following the presentation. The webcast will be archived and available for replay for a period of 30 days.

Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

On September 5, 2023 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, reported that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 4:30 p.m. E.T (Press release, Galera Therapeutics, SEP 5, 2023, View Source [SID1234634887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be accessible from the Investors page of Galera’s website, investors.galeratx.com(opens in a new tab). An archived version of the webcast will be available in the Events & Presentations section of the Investors page of Galera’s website for 30 days following the event.

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

On September 5, 2023 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference (Press release, G1 Therapeutics, SEP 5, 2023, View Source [SID1234634886]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the event will be accessible on the Events & Presentations page of View Source